ID: ALA4090197

Max Phase: Preclinical

Molecular Formula: C32H29Cl2N5O2S2

Molecular Weight: 650.66

Molecule Type: Small molecule

Representations

Canonical SMILES:  N/C(=N/C(=N\S(=O)(=O)c1ccc(Cl)cc1)N1CC(c2ccccc2)C(c2ccc(Cl)cc2)=N1)SCCCc1ccccc1

Standard InChI:  InChI=1S/C32H29Cl2N5O2S2/c33-26-15-13-25(14-16-26)30-29(24-11-5-2-6-12-24)22-39(37-30)32(38-43(40,41)28-19-17-27(34)18-20-28)36-31(35)42-21-7-10-23-8-3-1-4-9-23/h1-6,8-9,11-20,29H,7,10,21-22H2,(H2,35,36,38)

Standard InChI Key:  LAYHGXIWNHYDPC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 650.66

Molecular Weight (Monoisotopic): 649.1140

AlogP: 7.22

#Rotatable Bonds: 8

Polar Surface Area: 100.48

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 5.66

CX LogP: 8.23

CX LogD: 8.22

Aromatic Rings: 4

Heavy Atoms: 43

QED Weighted: 0.12

Np Likeness Score: -0.78

References

1. Iyer MR, Cinar R, Katz A, Gao M, Erdelyi K, Jourdan T, Coffey NJ, Pacher P, Kunos G..  (2017)  Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.,  60  (3): [PMID:28085283] [10.1021/acs.jmedchem.6b01504]

Source

Source(1):

• Scientific Literature